Vor Biopharma Inc.
VOR
Updated: 24/09/2026, 01:42:02
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
No summaries found.
- Share price
- $19.37
- Market cap
- $1.05B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Jean-Paul Kress
- Employees
- 76
- IPO date
- 05/02/2021
- Beta
- 1.715
- Last dividend
- $0.00
- Day range
- $18.89 – $22.02
- 52-week range
- $6.50 – $49.95
- 1-day performance
- -11.95%
- 1-year performance
- 198.00%
- Current drawdown (1Y)
- -61.22%
- CIK
- 0001817229
- CUSIP
- 929033207
- ISIN
- US9290332074
- Created
- 07/12/2025, 15:00:04
- Last update
- 24/09/2026, 01:42:02
Track Vor Biopharma Inc. with an AI analyst
See which prediction-market events move VOR, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Telitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in China
GlobeNewsWire • STOCK • 08/06/2026, 10:31:00
Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
GlobeNewsWire • STOCK • 14/05/2026, 10:30:00
Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade
Zacks Investment Research • STOCK • 07/05/2026, 12:55:37
Vor Biopharma: It's A Game Of Wait And See
Seeking Alpha • STOCK • 08/04/2026, 17:38:36
Vor Biopharma (VOR) Upgraded to Buy: Here's Why
Zacks Investment Research • STOCK • 02/04/2026, 15:01:05
Wall Street Analysts Predict a 107.82% Upside in Vor Biopharma (VOR): Here's What You Should Know
Zacks Investment Research • STOCK • 02/04/2026, 12:56:11
Vor Biopharma Inc. (VOR) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Seeking Alpha • STOCK • 06/03/2026, 00:45:55